ERBB2 and breast cancer: In order to analyze whether Bozepinib inhibits the HER2 signaling pathways in breast cancer cells, we treated the HER2 positive SKBR-3 cell line with 5 μM of Bozepinib and we analyzed the expression and activation of proteins involved in HER2 signaling at different times post-treatment by western blot analysis (Fig. 1A).